JP2018528191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528191A5 JP2018528191A5 JP2018508678A JP2018508678A JP2018528191A5 JP 2018528191 A5 JP2018528191 A5 JP 2018528191A5 JP 2018508678 A JP2018508678 A JP 2018508678A JP 2018508678 A JP2018508678 A JP 2018508678A JP 2018528191 A5 JP2018528191 A5 JP 2018528191A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- mixture
- mage
- peptogenic
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000018102 proteins Nutrition 0.000 claims description 122
- 102000004169 proteins and genes Human genes 0.000 claims description 122
- 108090000623 proteins and genes Proteins 0.000 claims description 122
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 55
- 235000004279 alanine Nutrition 0.000 claims description 42
- 108091033319 polynucleotide Proteins 0.000 claims description 40
- 102000040430 polynucleotide Human genes 0.000 claims description 40
- 239000002157 polynucleotide Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 37
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 36
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 34
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 34
- 235000014393 valine Nutrition 0.000 claims description 34
- 239000004474 valine Substances 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 30
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 30
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 30
- 235000014705 isoleucine Nutrition 0.000 claims description 30
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 30
- 229960000310 isoleucine Drugs 0.000 claims description 30
- 235000005772 leucine Nutrition 0.000 claims description 30
- 239000004471 Glycine Substances 0.000 claims description 26
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 20
- 235000004400 serine Nutrition 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 19
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 18
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 18
- 239000004473 Threonine Substances 0.000 claims description 18
- 235000008521 threonine Nutrition 0.000 claims description 18
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 16
- 235000006109 methionine Nutrition 0.000 claims description 16
- 229930182817 methionine Natural products 0.000 claims description 16
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 14
- 235000004554 glutamine Nutrition 0.000 claims description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 12
- 235000014304 histidine Nutrition 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 10
- 235000009582 asparagine Nutrition 0.000 claims description 10
- 229960001230 asparagine Drugs 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 235000003704 aspartic acid Nutrition 0.000 claims description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 235000013922 glutamic acid Nutrition 0.000 claims description 8
- 239000004220 glutamic acid Substances 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 8
- 235000008729 phenylalanine Nutrition 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 8
- 235000002374 tyrosine Nutrition 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 6
- -1 BAGE-I Proteins 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 239000007858 starting material Substances 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 4
- 102100040578 G antigen 7 Human genes 0.000 claims description 4
- 101710113436 GTPase KRas Proteins 0.000 claims description 4
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 claims description 4
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 claims description 4
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 claims description 4
- 108091036407 Polyadenylation Proteins 0.000 claims description 4
- 102100037686 Protein SSX2 Human genes 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 230000009260 cross reactivity Effects 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 201000004792 malaria Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000006641 stabilisation Effects 0.000 claims description 4
- 238000011105 stabilization Methods 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 2
- 101710163573 5-hydroxyisourate hydrolase Proteins 0.000 claims description 2
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical class CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 claims description 2
- 102100032959 Alpha-actinin-4 Human genes 0.000 claims description 2
- 101710115256 Alpha-actinin-4 Proteins 0.000 claims description 2
- 244000303258 Annona diversifolia Species 0.000 claims description 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 2
- 101000874387 Astacus leptodactylus Sarcoplasmic calcium-binding protein 1 Proteins 0.000 claims description 2
- 108060000903 Beta-catenin Proteins 0.000 claims description 2
- 102000015735 Beta-catenin Human genes 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 101150108242 CDC27 gene Proteins 0.000 claims description 2
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims description 2
- 102100026548 Caspase-8 Human genes 0.000 claims description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 claims description 2
- 108010072210 Cyclophilin C Proteins 0.000 claims description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 2
- 102100039699 G antigen 4 Human genes 0.000 claims description 2
- 101710092267 G antigen 5 Proteins 0.000 claims description 2
- 102100039698 G antigen 5 Human genes 0.000 claims description 2
- 101710092269 G antigen 6 Proteins 0.000 claims description 2
- 102100039713 G antigen 6 Human genes 0.000 claims description 2
- 102100039788 GTPase NRas Human genes 0.000 claims description 2
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims description 2
- 101710197901 Galectin-3-binding protein Proteins 0.000 claims description 2
- 108010036972 HLA-A11 Antigen Proteins 0.000 claims description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 claims description 2
- 101000924350 Homo sapiens Alpha-N-acetylglucosaminidase Proteins 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 claims description 2
- 101000866749 Homo sapiens Elongation factor 2 Proteins 0.000 claims description 2
- 101000886678 Homo sapiens G antigen 2D Proteins 0.000 claims description 2
- 101000886136 Homo sapiens G antigen 4 Proteins 0.000 claims description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 2
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000962088 Homo sapiens NBAS subunit of NRZ tethering complex Proteins 0.000 claims description 2
- 101000610208 Homo sapiens Poly(A) polymerase gamma Proteins 0.000 claims description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 2
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 claims description 2
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 claims description 2
- 101001073409 Homo sapiens Retrotransposon-derived protein PEG10 Proteins 0.000 claims description 2
- 101000973629 Homo sapiens Ribosome quality control complex subunit NEMF Proteins 0.000 claims description 2
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 claims description 2
- 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 108010052919 Hydroxyethylthiazole kinase Proteins 0.000 claims description 2
- 108010027436 Hydroxymethylpyrimidine kinase Proteins 0.000 claims description 2
- 108010030506 Integrin alpha6beta4 Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims description 2
- 102000016200 MART-1 Antigen Human genes 0.000 claims description 2
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 2
- 102100025136 Macrosialin Human genes 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 claims description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 102000003505 Myosin Human genes 0.000 claims description 2
- 108060008487 Myosin Chemical class 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 102000036673 PRAME Human genes 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims description 2
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 2
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 claims description 2
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims description 2
- 102100040153 Poly(A) polymerase gamma Human genes 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 claims description 2
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 claims description 2
- 102100035844 Retrotransposon-derived protein PEG10 Human genes 0.000 claims description 2
- 102100022213 Ribosome quality control complex subunit NEMF Human genes 0.000 claims description 2
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 2
- 101800001271 Surface protein Proteins 0.000 claims description 2
- 108700019889 TEL-AML1 fusion Proteins 0.000 claims description 2
- 101150031162 TM4SF1 gene Proteins 0.000 claims description 2
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 claims description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 claims description 2
- 102100033598 Triosephosphate isomerase Human genes 0.000 claims description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 claims description 2
- 241000907316 Zika virus Species 0.000 claims description 2
- 230000009824 affinity maturation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 239000013566 allergen Substances 0.000 claims description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims description 2
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 108010021994 cytomegalovirus matrix protein 65kDa Proteins 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 238000012817 gel-diffusion technique Methods 0.000 claims description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 2
- 230000000951 immunodiffusion Effects 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 238000000111 isothermal titration calorimetry Methods 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 210000002752 melanocyte Anatomy 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims description 2
- 238000004091 panning Methods 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 238000002823 phage display Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000000159 protein binding assay Methods 0.000 claims description 2
- 238000002818 protein evolution Methods 0.000 claims description 2
- 230000002797 proteolythic effect Effects 0.000 claims description 2
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 108010014186 ras Proteins Proteins 0.000 claims description 2
- 102000016914 ras Proteins Human genes 0.000 claims description 2
- 238000002702 ribosome display Methods 0.000 claims description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 2
- 238000003239 susceptibility assay Methods 0.000 claims description 2
- 101150047061 tag-72 gene Proteins 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108010020589 trehalose-6-phosphate synthase Proteins 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 239000002435 venom Substances 0.000 claims description 2
- 231100000611 venom Toxicity 0.000 claims description 2
- 210000001048 venom Anatomy 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022099482A JP2022123088A (ja) | 2015-08-19 | 2022-06-21 | 抗体を生成する新規な方法 |
| JP2025017152A JP2025081372A (ja) | 2015-08-19 | 2025-02-04 | 抗体を生成する新規な方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562207022P | 2015-08-19 | 2015-08-19 | |
| US62/207,022 | 2015-08-19 | ||
| PCT/US2016/047620 WO2017031353A1 (en) | 2015-08-19 | 2016-08-18 | Novel methods of generating antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022099482A Division JP2022123088A (ja) | 2015-08-19 | 2022-06-21 | 抗体を生成する新規な方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528191A JP2018528191A (ja) | 2018-09-27 |
| JP2018528191A5 true JP2018528191A5 (enExample) | 2019-09-12 |
Family
ID=56802717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508678A Withdrawn JP2018528191A (ja) | 2015-08-19 | 2016-08-18 | 抗体を生成する新規な方法 |
| JP2022099482A Pending JP2022123088A (ja) | 2015-08-19 | 2022-06-21 | 抗体を生成する新規な方法 |
| JP2025017152A Pending JP2025081372A (ja) | 2015-08-19 | 2025-02-04 | 抗体を生成する新規な方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022099482A Pending JP2022123088A (ja) | 2015-08-19 | 2022-06-21 | 抗体を生成する新規な方法 |
| JP2025017152A Pending JP2025081372A (ja) | 2015-08-19 | 2025-02-04 | 抗体を生成する新規な方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11384138B2 (enExample) |
| EP (1) | EP3337822A1 (enExample) |
| JP (3) | JP2018528191A (enExample) |
| CA (1) | CA2995838A1 (enExample) |
| WO (1) | WO2017031353A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7048608B2 (ja) | 2016-08-15 | 2022-04-05 | チルドレンズ メディカル センター コーポレーション | Ａｐｏｍ－ｆｃ融合タンパク質、それとスフィンゴシン１－リン酸（ｓ１ｐ）との複合体、および血管疾患および非血管疾患を処置するための方法 |
| AU2017366924A1 (en) | 2016-12-01 | 2019-07-11 | The Trustees Of Columbia University In The City Of New York | Serological assay for Zika virus infection |
| CN111836646A (zh) * | 2017-08-15 | 2020-10-27 | 儿童医学中心公司 | Apom-fc融合蛋白及其用途 |
| WO2019118918A1 (en) * | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Cd19 variants |
| SG11202012653XA (en) | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
| US12415847B2 (en) | 2018-10-12 | 2025-09-16 | Children's Medical Center Corporation | ApoM-Fc fusion proteins for treating lung diseases |
| WO2020219896A1 (en) * | 2019-04-26 | 2020-10-29 | Beijing Xuanyi Pharmasciences Co., Ltd. | Cd80 variant proteins and uses thereof |
| TW202116797A (zh) | 2019-07-30 | 2021-05-01 | 大學健康網絡 | Ｉｉ類ｍｈｃ分子及其使用方法 |
| TWI881991B (zh) * | 2019-07-30 | 2025-05-01 | 大學健康網絡 | Ｉｉ類ｍｈｃ分子及其使用方法 |
| CN110592032B (zh) * | 2019-10-14 | 2021-04-13 | 北京理工大学 | 泛素连接酶Smurf1突变体、编码基因及用途 |
| CN110760597B (zh) * | 2019-11-22 | 2022-08-23 | 西北农林科技大学 | 一种检测黄牛ncstn基因拷贝数变异的方法及其应用 |
| EP3845554A1 (en) * | 2019-12-30 | 2021-07-07 | Technische Universität Dortmund | Method for determining 5-methylcytosine configurations in dna |
| EP4208197A1 (en) * | 2020-09-04 | 2023-07-12 | Rutgers, The State University of New Jersey | Sars-cov-2 vaccines and antibodies |
| WO2022076947A1 (en) * | 2020-10-09 | 2022-04-14 | The General Hospital Corporation | Peptide inhibitors of glioma-associated oncogene derived from the coiled-coil dimerization domain of kif7 |
| EP4305190A4 (en) | 2021-03-11 | 2025-03-26 | Iggenix, Inc. | METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION |
| CN117482090A (zh) * | 2023-11-07 | 2024-02-02 | 中国人民解放军空军军医大学 | 一种化合物在调节tgr5受体活性及其在神经保护或抑郁症治疗中的应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| EP0582595A1 (en) | 1991-04-26 | 1994-02-16 | Surface Active Limited | Novel antibodies, and methods for their use |
| US5661133B1 (en) | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| ATE182651T1 (de) | 1992-06-09 | 1999-08-15 | Hoppe Ag | Riegel und türschloss |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| EP1658772A3 (en) | 1995-01-17 | 2007-01-17 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US7118874B2 (en) | 1998-10-09 | 2006-10-10 | Variation Biotechnologies Inc. | Immunogenic formulation and process for preparation thereof |
| US6511832B1 (en) | 1999-10-06 | 2003-01-28 | Texas A&M University System | In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase |
| EP1278551A2 (en) | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
| FR2868318B1 (fr) | 2004-04-01 | 2012-11-16 | Commissariat Energie Atomique | Antigene tat stabilise et ses applications pour la vaccination anti-vih |
| US20080038280A1 (en) * | 2004-10-14 | 2008-02-14 | Government Of The United States Of America | A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines |
| WO2008064488A1 (en) | 2006-11-30 | 2008-06-05 | Variation Biotechnologies Inc. | Influenza vaccine formulation |
| US20110195089A1 (en) | 2008-10-08 | 2011-08-11 | The Adminstrators Of The Tulane Educational Fund | Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens |
| CN102060929A (zh) * | 2010-06-07 | 2011-05-18 | 夏书奇 | T细胞免疫平衡肽 |
-
2016
- 2016-08-18 JP JP2018508678A patent/JP2018528191A/ja not_active Withdrawn
- 2016-08-18 EP EP16757810.3A patent/EP3337822A1/en active Pending
- 2016-08-18 CA CA2995838A patent/CA2995838A1/en active Pending
- 2016-08-18 WO PCT/US2016/047620 patent/WO2017031353A1/en not_active Ceased
- 2016-08-18 US US15/753,321 patent/US11384138B2/en active Active
-
2022
- 2022-06-08 US US17/835,370 patent/US20230042877A1/en not_active Abandoned
- 2022-06-21 JP JP2022099482A patent/JP2022123088A/ja active Pending
-
2025
- 2025-02-04 JP JP2025017152A patent/JP2025081372A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022123088A (ja) | 抗体を生成する新規な方法 | |
| US20230330210A1 (en) | Stabilized influenza hemagglutinin stem region trimers and uses thereof | |
| JP2010533649A5 (enExample) | ||
| Ellebedy et al. | Re-engaging cross-reactive memory B cells: the influenza puzzle | |
| Rajendran et al. | Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: evidence for original antigenic sin | |
| JP7269166B2 (ja) | 免疫抑制抵抗性が増したｔ細胞 | |
| Zhao et al. | Advances in the study of HLA-restricted epitope vaccines | |
| Fernandez-Tejada et al. | Designing synthetic vaccines for HIV | |
| JP2012500652A5 (enExample) | ||
| US12612461B2 (en) | Single domain antibodies against CLL-1 | |
| Gupta et al. | Receptor-ligand based molecular interaction to discover adjuvant for immune cell TLRs to develop next-generation vaccine | |
| Sastry et al. | Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody | |
| US10906943B2 (en) | Virus-like particles with high-density coating for inducing the expression of antibodies | |
| Lin et al. | Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines | |
| JP2024029012A (ja) | ペプチド交換蛋白質 | |
| US20170216425A1 (en) | Avoiding narcolepsy risk in influenza vaccines | |
| Shah et al. | Challenges and considerations in multi-epitope vaccine design surrounding toll-like receptors | |
| JP2016523237A (ja) | タンパク質−細胞コンジュゲート、その調製法および使用 | |
| KR20210097833A (ko) | 신규한 포유동물 발현 인간 면역결핍 바이러스 외피 단백질 항원 | |
| Simerska et al. | Ovalbumin lipid core peptide vaccines and their CD4+ and CD8+ T cell responses | |
| Adler-Moore et al. | Monomeric M2e antigen in VesiVax® liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2e | |
| Brouwer et al. | Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses | |
| JP7329529B2 (ja) | ヘマグルチニンを含む広範に防御的なワクチン組成物を生成する方法 | |
| Mollica et al. | Strategies for developing tuberculosis vaccines: emerging approaches | |
| Goll et al. | The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination |